(DIR) Return Create A Forum - Home --------------------------------------------------------- MS Speaks (HTM) https://msspeaks.createaforum.com --------------------------------------------------------- ***************************************************** (DIR) Return to: BRIUMVI (ublituximab) ***************************************************** #Post#: 1839-------------------------------------------------- Two new MS drugs being developed: umbralisib (TGR-1202), ublitux imab (TG-1101) By: agate Date: October 3, 2017, 8:14 pm --------------------------------------------------------- From Multiple Sclerosis News Today (October 3, 2017) comes news of two new MS drugs in the pipeline: (HTM) https://multiplesclerosisnewstoday.com/2017/10/03/national-ms-society-tg-therapeutics-partner-to-advance-tgr-1202-for-progressive-ms/ (HTM) https://multiplesclerosisnewstoday.com/2017/10/03/national-ms-society-tg-therapeutics-partner-to-advance-tgr-1202-for-progressive-ms/ #Post#: 1979-------------------------------------------------- (ACTRIMS) 6-month results of phase 2a multicenter study of ublit uximab in RMS By: agate Date: February 7, 2018, 7:59 pm --------------------------------------------------------- Abstract of a paper on ublituximab presented at the annual ACTRIMS (Americas Committee for Treatment and Research in Multiple Sclerosis) conference in San Diego, February 1-3, 2018. The paper is entitled "6-month results of a Phase 2a multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in relapsing multiple sclerosis."[center][/center]: (HTM) https://actrims.confex.com/actrims/2018/meetingapp.cgi/Paper/2742 #Post#: 2112-------------------------------------------------- (CMSC2018) MS patients treated w/ublituximab show benefits in Ph ase 2 study By: agate Date: June 9, 2018, 8:26 pm --------------------------------------------------------- From Multiple Sclerosis News Today (June 5, 2018)--"CMSC2018: MS Patients Treated with Ublituximab Show Benefits in Phase 2 Study" (results presented at the Consortium of Multiple Sclerosis Centers 2018 conference, May 30 - June 2): (HTM) https://multiplesclerosisnewstoday.com/2018/06/05/cmsc2018-phase-2-study-supports-ublituximab-efficacy-in-relapsing-multiple-sclerosis/?utm_source=Multiple+Sclerosis&utm_campaign=6819f167ac-RSS_US_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-6819f167ac-71286581 *****************************************************